ArticleCommunications medicine2025
Analysis of travel-time to HIV treatment in sub-Saharan Africa reveals inequities in access to antiretrovirals.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Second-line antiretroviral therapy success rates and predictors among people living with HIV in Rwanda, 2019-2023.BMC infectious diseases · 2026Article
- Quantifying the impact of health service delivery barriers on access to healthcare: a case study of antiretroviral therapy in Mali.BMJ global health · 2026Article
- Parkinsonism in people with virally suppressed HIV.The lancet. HIV · 2026Review
- Analysis of travel-time to HIV treatment in sub-Saharan Africa reveals inequities in access to antiretrovirals.Communications medicine · 2025Article
- The global response to HIV/AIDS in sub-Saharan Africa: achievements, challenges, and perspectives for the future.Frontiers in public health · 2025Review
- Beyond Viral Suppression: Navigating Structural Barriers, Aging and Frailty, Drug Resistance, Therapeutic Innovations, and Reproductive Health Challenges in the Global HIV/AIDS Epidemic.Journal of AIDS and HIV treatment · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundUNAIDS proposes ending inequalities in access to HIV treatment. We use data from nationally-representative Population-Based HIV Impact Assessment (PHIA) surveys for Eswatini, Malawi, and Zambia to identify inequities in one-way travel-time to access antiretroviral therapy (ART) for people with HIV (PWH).
methodsUsing biometric data from the PHIAs, we construct Epidemic Surface Prevalence maps and estimate treatment coverage. Self-reported travel-time data were fit using logistic cumulative distribution functions. Multivariable logistic regression models were used to examine relationships between travel-time, urban-rural residency, age, and sex.
resultsWe find the majority of PWH on ART are women: Eswatini (69.4%), Malawi (64.8%), Zambia (63.0%). The majority on ART reside in rural areas in Malawi (74.6%) and Eswatini (71.0%), but in urban areas in Zambia (61.9%). Travel-time distribution functions show, on average, PWH in Eswatini have the shortest travel-times; travel-times in Malawi are slightly longer than in Zambia. 56.4% (Malawi), 50.5% (Zambia), and 37.4% (Eswatini) of treated individuals could not access ART within one hour; many travel more than two hours: 20.6% (Zambia), 19.0% (Malawi), 10.5% (Eswatini). In all countries, the odds of traveling one or more hours are significantly higher in rural than urban areas. In Eswatini and Zambia, women have significantly higher odds than men of traveling one or more hours.
conclusionsMany PWH spend considerable time traveling to access ART. Substantial inequities exist, disadvantaging rural populations in all three countries, and women in Eswatini and Zambia. Achieving UNAIDS' goal will require identifying drivers of inequities and designing strategies to minimize them.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.